S-17092 is a drug which acts as a selective inhibitor of the enzyme Prolyl endopeptidase.[1] This enzyme is involved in the metabolic breakdown of a number of neuropeptide neurotransmitters in the brain,[2][3] and so inhibiting the action of the enzyme increases the activity of these neuropeptides. This produces nootropic effects which make S-17092 a promising and novel treatment for neurodegenerative conditions such as Alzheimer's disease and Parkinson's disease.[4][5]
[edit] See also
[edit] References
- ^ Barelli H, Petit A, Hirsch E, Wilk S, De Nanteuil G, Morain P, Checler F. S 17092-1, a highly potent, specific and cell permeant inhibitor of human proline endopeptidase. Biochemical and Biophysical Research and Communications. 1999 Apr 21;257(3):657-61. PMID 10208839
- ^ Bellemère G, Morain P, Vaudry H, Jégou S. Effect of S 17092, a novel prolyl endopeptidase inhibitor, on substance P and alpha-melanocyte-stimulating hormone breakdown in the rat brain. Journal of Neurochemistry. 2003 Mar;84(5):919-29. doi:10.1046/j.1471-4159.2003.01536.x PMID 12603817
- ^ Bellemère G, Vaudry H, Morain P, Jégou S. Effect of prolyl endopeptidase inhibition on arginine-vasopressin and thyrotrophin-releasing hormone catabolism in the rat brain. Journal of Neuroendocrinology. 2005 May;17(5):306-13. PMID 15869566
- ^ Morain P, Lestage P, De Nanteuil G, Jochemsen R, Robin JL, Guez D, Boyer PA. S 17092: a prolyl endopeptidase inhibitor as a potential therapeutic drug for memory impairment. Preclinical and clinical studies. CNS Drug Reviews. 2002 Spring;8(1):31-52. PMID 12070525
- ^ Morain P, Boeijinga PH, Demazières A, De Nanteuil G, Luthringer R. Psychotropic profile of S 17092, a prolyl endopeptidase inhibitor, using quantitative EEG in young healthy volunteers. Neuropsychobiology. 2007;55(3-4):176-83. PMID 17700042
(what is this?) (verify)
